Edwards Lifesciences $39M Securities Class Action Settlement

Investors who purchased or otherwise acquired Edwards Lifesciences Corp. common stock between Feb. 6, 2024, and July 24, 2024, may be eligible to claim a cash payment from a class action settlement.

Edwards Lifesciences and CEO Bernard J. Zovighian agreed to pay $39 million to settle a securities class action lawsuit alleging they made materially false and misleading statements and omissions. The lawsuit claimed they misrepresented the growth prospects of the company's core product, its transcatheter aortic valve replacement platform.

Who can file a claim?

The settlement includes all persons and entities who purchased or otherwise acquired Edwards Lifesciences Corp. common stock between Feb. 6, 2024, and July 24, 2024, inclusive, and suffered damaged as a result.

Additional details

• Both individuals and entities can be class members.
• Each separate legal entity or separately managed account must submit a separate claim.
• The beneficial owner or a legal representative must submit the claim.
• Joint owners must each sign the claim form.
• Agents, executors, administrators, guardians and trustees may submit claims on behalf of others and must provide proof of authority.
• Participants in and beneficiaries of an Edwards employee benefit plan covered by ERISA should not include transactions made through the plan on their claim form.

How much can class members get?

The total settlement fund is $39,000,000. The amount each class member will receive depends on several factors:

• The number of valid claims submitted
• The number of shares purchased or acquired during the class period
• The timing of each investor purchase, sale and holding
• The total recognized claims of all claimants

The settlement administrator will distribute payments on a pro rata basis according to the court-approved plan of allocation:

• The estimated average recovery per eligible share is approximately $0.66 before deductions for attorneys' fees and expenses, taxes and administration costs.
• Actual payments may be higher or lower depending on individual claims and the total number of valid claims.
• The settlement administrator will calculate each class member's payment based on the recognized loss amount assigned to each share.
• Recognized loss amounts depend on purchase and sale timing. The settlement administrator will calculate them using the court-approved plan of allocation.
• For shares sold before the close of trading on July 24, 2024, the recognized loss is $0.
• For shares sold from July 25, 2024, through Oct. 22, 2024, the recognized loss is the lowest of $24.17, the purchase price minus the sale price or the purchase price minus the average closing price through the sale date (Table A on Page 22 of the settlement notice).
• For shares held as of the close of trading on Oct. 22, 2024, the recognized loss is the lesser of $24.17 or the purchase price minus $66.77 (the average closing price from July 25, 2024, through Oct. 22, 2024).
• The settlement administrator will set any recognized loss that calculates to a negative number to $0.

• If total recognized claims exceed the net settlement fund, the settlement administrator will reduce payments on a pro rata basis.
• Class members whose payment would be less than $10 will not receive a payout.

How to claim an Edwards Lifesciences securities class action settlement payment

Class members may file a claim online or download, print and complete the PDF claim form and mail it to the settlement administrator. The claim deadline is Dec. 2, 2026.

Settlement administrator's mailing address: Edwards Lifesciences Securities Litigation, c/o Kroll Settlement Administration, P.O. Box 5014, New York, NY 10150-5014

Proof or documentation required to submit a claim

All class members must provide the last four digits of their Social Security number or taxpayer identification number. They must also provide holdings and transaction information, including:

• Number of shares held as of Feb. 6, 2024
• Trade dates for purchases and sales from Feb. 6, 2024, through Oct. 22, 2024
• Number of shares purchased, acquired or sold
• Total purchase, sale or acquisition price
• Number of shares held as of Oct. 22, 2024

Class members must also provide documentation to support their holdings and transactions in Edwards common stock. Acceptable proof includes:

• Broker confirmation slips
• Broker account statements
• Authorized statements from a broker containing the transactional and holding information found in a confirmation slip or account statement

Payout options

• Physical check

$39 million settlement fund

The $39,000,000 settlement fund includes:

• Settlement administration costs: To be determined
• Attorneys' fees: Up to $9,750,000
• Attorneys' expenses: Up to $195,000
• Payments to eligible class members: Remainder of the fund

Important dates

• Deadline to file a claim: Dec. 2, 2026
• Opt-out deadline: Dec. 2, 2026
• Fairness hearing: Dec. 16, 2026

When is the Edwards Lifesciences securities class action settlement payout date?

The settlement administrator will issue payments after it completes processing and the court resolves any appeals and grants final approval to the settlement.

Why did this class action settlement happen?

The class action lawsuit alleged Edwards Lifesciences and Zovighian made false and misleading statements regarding the growth prospects of the company's TAVR platform. The plaintiffs claimed these statements inflated Edwards' stock price and caused investor losses when corrective information entered the market in July 2024.

The defendants denied all allegations of wrongdoing but agreed to settle to avoid the burden, expense and uncertainty of continued litigation.

Sources

1. Claim form
2. Class notice